Implant-Related Medication-related Osteonecrosis of the Jaw in Patients Receiving Bone-modifying Agent Therapy: A Retrospective Study on Onset Timing and Causes

Jangwoo Son; Kang-Min Ahn

doi:10.32542/implantology.2024018

All Issue

2024 Vol.28, Issue 4 Next Page

Original Article

Implant-Related Medication-related Osteonecrosis of the Jaw in Patients Receiving Bone-modifying Agent Therapy: A Retrospective Study on Onset Timing and Causes

31 December 2024. pp. 169-181

PDF XML

Abstract

Purpose: Medication-related osteonecrosis of the jaw (MRONJ) is a significant complication associated with bone-modifying agents (BMAs). This study addresses the gap in understanding how local factors, such as peri-implantitis, extractions, surgical trauma, and timing of implant placement relative to BMA therapy, affect MRONJ development around dental implants.

Materials and Methods: We conducted a retrospective analysis of 38 patients who developed peri-implant MRONJ following BMA therapy at Asan Medical Center between 2008 and 2024. Using the 2022 American Association of Oral and Maxillofacial Surgery criteria, we diagnosed and staged MRONJ. We examined the patient profiles, BMA regimens, implant placement timing, and MRONJ onset. Based on this, the subjects were divided into three groups (Group 1: implant placement before BMA administration, Group 2: implant placement after BMA administration, MRONJ occurrence within 1 year after surgery, Group 3: implant placement after BMA administration, MRONJ occurrence more than 1 year after surgery). The causes were classified as chronic inflammation (peri-implantitis) or acute inflammation (trauma caused by surgery or tooth extraction), assessed through radiographic and clinical examinations. We also observed the occurrence of MRONJ at other oral sites.

Results: The cohort comprised 37 patients with osteoporosis and one patient with breast cancer. BMA treatment included oral bisphosphonates (15), intravenous bisphosphonates (7), denosumab (3), and combination therapies (13). MRONJ occurred in 21 cases (group 1, 55.2%) when implants were placed before BMA administration and in 17 cases (44.7%) when placed after administration. Among the latter, nine cases (group 2, 23.7%) developed within 1 year of implant placement, and eight cases (group 3, 21.0%) occurred more than 1 year after placement. Chronic inflammation (peri-implantitis) was the primary cause in 26 patients (68.4%), whereas acute inflammation (trauma and other local factors) was the primary cause in 12 patients (31.6%). Nine patients developed MRONJ at additional oral sites. Five cases showed MRONJ-free implants placed simultaneously with the affected implants.

Conclusion: The main direct causes of MRONJ differ depending on the timing of BMA administration and implant placement. In cases with osseointegration (Groups 1 and 3), chronic inflammation was the primary cause of MRONJ, whereas acute inflammation was the main cause immediately after surgery (Group 2). Additionally, local infections and inflammation spread from adjacent tooth extractions can cause extensive lesions around MRONJ sites.

Keywords

Bone-modifying agent

Implant surgery

Medication-related osteonecrosis of the jaw

Peri-implantitis, Tooth extraction

References

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg 2022;80:920-43.

10.1016/j.joms.2022.02.00835300956

Migliorati CA. Oral Complications in Cancer Patients-Medication-Related Osteonecrosis of the Jaw (MRONJ). Front Oral Health 2022;3:866871.

10.3389/froh.2022.86687135558547PMC9086704

Tetradis S, Allen MR, Ruggiero SL. Pathophysiology of Medication-Related Osteonecrosis of the Jaw-A Minireview. JBMR Plus 2023;7:e10785.

10.1002/jbm4.1078537614299PMC10443081

Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015;30:3-23.

10.1002/jbmr.240525414052

Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G. Medication-related osteonecrosis of the jaw: Clinical and practical guidelines. J Int Soc Prev Community Dent 2016;6:97-104.

10.4103/2231-0762.17874227114946PMC4820581

Ikesue H, Mouri M, Tomita H, Hirabatake M, Ikemura M, Muroi N, et al. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases. Support Care Cancer 2021;29:4763-72.

10.1007/s00520-021-06018-x33527228PMC8236436

Nicolatou-Galitis O, Schiodt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol 2019;127:117-35.

10.1016/j.oooo.2018.09.00830393090

Holzinger D, Seemann R, Matoni N, Ewers R, Millesi W, Wutzl A. Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2014;72:1937 e1931-8.

10.1016/j.joms.2014.04.03725234534

Pichardo SEC, van der Hee JG, Fiocco M, Appelman-Dijkstra NM, van Merkesteyn JPR. Dental implants as risk factors for patients with medication-related osteonecrosis of the jaws (MRONJ). Br J Oral Maxillofac Surg 2020;58:771-6.

10.1016/j.bjoms.2020.03.02232631756

Granate-Marques A, Polis-Yanes C, Seminario-Amez M, Jane-Salas E, Lopez-Lopez J. Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: Systematic review. Med Oral Patol Oral Cir Bucal 2019;24:e195-203.

10.4317/medoral.2269130818312PMC6441601

Giovannacci I, Meleti M, Manfredi M, Mortellaro C, Greco Lucchina A, Bonanini M, et al. Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis? J Craniofac Surg 2016;27:697-701.

10.1097/SCS.000000000000256427092912

Kwon TG, Lee CO, Park JW, Choi SY, Rijal G, Shin HI. Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin Oral Implants Res 2014;25:632-40.

10.1111/clr.1208823278625

Lazarovici TS, Yahalom R, Taicher S, Schwartz-Arad D, Peleg O, Yarom N. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg 2010; 68:790-6.

10.1016/j.joms.2009.09.01720307764

He L, Sun X, Liu Z, Qiu Y, Niu Y. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int J Oral Sci 2020;12:30.

10.1038/s41368-020-00093-233087699PMC7578793

Lee ES, Tsai MC, Lee JX, Wong C, Cheng YN, Liu AC, et al. Bisphosphonates and Their Connection to Dental Procedures: Exploring Bisphosphonate-Related Osteonecrosis of the Jaws. Cancers (Basel) 2023;15.

10.3390/cancers1522536638001626PMC10670230

Katsarelis H, Shah NP, Dhariwal DK, Pazianas M. Infection and medication-related osteonecrosis of the jaw. J Dent Res 2015;94:534-9.

10.1177/002203451557202125710950

Kwon YD, Jo H, Kim JE, Ohe JY. A clinical retrospective study of implant as a risk factor for medication-related osteonecrosis of the jaw: surgery vs loading? Maxillofac Plast Reconstr Surg 2023;45:31.

10.1186/s40902-023-00398-237707716PMC10501104

Information

Publisher :The Korean Academy of Oral & Maxillofacial Implantology
Publisher(Ko) :대한구강악안면임플란트학회
Journal Title :Journal of implantology and applied sciences
Journal Title(Ko) :대한구강악안면임플란트학회지
Volume : 28
No :4
Pages :169-181
Received Date : 2024-09-29
Revised Date : 2024-10-06
Accepted Date : 2024-12-05
DOI :https://doi.org/10.32542/implantology.2024018

Journal of implantology and applied sciences ISSN:2765-7833(Print) 2765-7841(Online) 대한구강악안면임플란트학회지

All Issue